Modi flouted election rules, book him: EC tells Gujarat cops

April 30, 2014

Ahmedabad, Apr 30: The Election Commission (EC) on Wednesday ordered the Gujarat administration to lodge a complaint/FIR against Narendra Modi for delivering a politically charged speech and displaying the BJP's poll symbol lotus in violation of an electoral law soon after exercising his franchise in Gandhinagar.

Modi_voting

Congress' legal department secretary KC Mittal lodged a complaint with the poll body, saying Modi's speech and display of symbol violated the Representation of the People (RP) Act and demanded an FIR be registered against him.

Asking the state administration to furnish a compliance report by 6pm, the poll body said, "The Commission is of the view that by holding that meeting and also by addressing the same today when the polling is going on in the entire state of Gujarat and in different parts of the country, Narendra Modi has violated the provisions of sections 126 (1)(a) and 126 (l)(b) of RP Act 1951."

Though it is a normal practice for top leaders to make brief statements before the media after casting their votes, what irked Modi's rivals was a high-voltage speech in which he slammed the Congress.

The BJP's prime ministerial nominee also clicked a selfie prominently displaying the party symbol and posted it on Twitter. After casting his vote, Modi not only fervently asked the electorate to support the BJP but also said the Congress had already accepted defeat.

Acting tough, the EC said all the TV channels that carried the proceedings of the meeting and displayed the election matter should also be booked under Section 126 (l) (b) "by filing separate complaints/FlRs against those channels".

According to the Section 126 (1) (a) and (b) of the Representation of the People (RP) Act, public meetings are prohibited during the period of 48 hours ending with the hour fixed for conclusion of polling.

It also says "no person shall… display to the public any election matter by means of cinematograph, television or other similar apparatus."

The EC took the decision after going through the video recording of the address of Modi at a meeting in Gandhinagar after he exercised his franchise. The BJP's PM nominee is in the fray from Varanasi in Uttar Pradesh and Vadodara in Gujarat, where polling was held on Wednesday.

The EC said the substance, tone and tenor of the address made by Modi was "in the nature of political speech intended and calculated to influence and affect the result of elections".

The poll watchdog also referred to its April 9 order that said people cannot enter a polling station with caps, shawls and clothes bearing symbol of any political party.

Modi's speech did not go down well with the Aam Aadmi Party too.

Its Gujarat convenor Sukhdev Patel said, "Modi is a senior politician. He should know his limits."

The BJP defended Modi, saying he had acted within limits. It hit out at the Congress and claimed it was an attempt by the "rattled" party to divert the attention of the people.

"As far as Modi is concerned, he has acted within the ambit of the model code of conduct," BJP general secretary J P Nadda told reporters.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 24,2020

Kochi, Apr 24: The central government on Thursday submitted a statement in the Kerala High Court on the three petitions challenging the contract between Kerala government and US-based data analytics company Sprinklr.

Assistant Solicitor General P Vijayakumar filed the statement on behalf of the central government, which is the second respondent in the case.

The statement said that the contract between the Kerala government and Sprinklr dilutes the rights of the people. It stated the contract does not specify the amount of compensation that individuals should receive in case of breach of privacy or misuse of information.

It also said that it was not clear whether the information was collected and handed over to the data analytics firm with full consent of the patients (suspected and otherwise).

''It is always preferable to utilise the services available in the government sector for sharing sensitive data required for analytical purposes.

The Government of India has introduced the 'Aarogya Setu' application for collection of health data and about seven crore Indian citizens have already downloaded the same. All the state governments are advised to promote the said application for fighting the pandemic," the statement said.

It was further submitted that the "Government of India with the support of NIC is capable of providing all the requirements relating to data storage, processing and application which are being offered the third respondent, if a request to that effect comes from the state government."

Kerala Congress leader Ramesh Chennithala and BJP state president K Surendran had earlier approached the Kerala High Court seeking cancellation of the state government's agreement with Sprinklr for processing of data related to COVID-19 patients.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 1,2020

New Delhi, Jan 1: Newly-appointed Chief of the Defence Staff General Bipin Rawat on Wednesday said the armed forces stay away from politics and work as per the directives of the government of the day, remarks that come amid allegations that the forces were being politicised.

Gen Rawat also said that his focus as CDS will be to integrate the efforts of the three services and to work as a team.

"We keep ourselves away from politics. We act according to the directives of the government of the day," he said.

Gen Rawat said his focus will be to ensure best and optimal use of resources allocated to the three services.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.